M&As this week: Oncolys BioPharma, Alira Health, NL-HOLDING

23rd February 2018 (Last Updated February 23rd, 2018 00:00)

Oncolys BioPharma has agreed to purchase an additional 8.4% stake in Precision Virologics from US-based oncolytic virus immunotherapy products developer Unleash Immuno Oncolytics.

Oncolys BioPharma has agreed to purchase an additional 8.4% stake in Precision Virologics from US-based oncolytic virus immunotherapy products developer Unleash Immuno Oncolytics.

As part of the acquisition, Oncolys BioPharma will purchase 294,118 shares of Precision Virologics from Unleash for $0.33m. Oncolys BioPharma’s stake will then increase from the existing 14.6% to 23%.

"Alira Health has announced the acquisition of Clinical Assistance Programs (CAP)."

Oncolys BioPharma is a biopharmaceutical company based in Japan, while Precision Virologics is a biotechnology company based in the US.

Unleash Immuno Oncolytics has simultaneously announced plans to raise $3m through the private placement of convertible bonds.

Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).

Based in the US, Alira Health is an international healthcare and life science advisory firm, while CAP is involved in providing clinical trial management and consulting services.

NL-HOLDING has acquired ProCrea Group, Archimed and Instituto de Medicina Reproductiva (IMER).

The German healthcare services provider has acquired all three companies in partnership with Oaktree Capital Management.

ProCrea and Instituto de Medicina Reproductiva are assisted-reproduction service providers based in Switzerland and Spain respectively, while Archimedis is an Italian company involved in the provision of specialised diagnostic services.